Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
18
Date Issued
2023-06-20
Author(s)
Chi, Kim N
Rathkopf, Dana
Smith, Matthew R
Efstathiou, Eleni
Attard, Gerhardt
Olmos, David
Lee, Ji Youl
Small, Eric J
Pereira de Santana Gomes, Andrea J
Roubaud, Guilhem
Saad, Marniza
Zurawski, Bogdan
Sakalo, Valerii
Mason, Gary E
Francis, Peter
Wang, George
Wu, Daphne
Diorio, Brooke
Lopez-Gitlitz, Angela
Sandhu, Shahneen
Abstract
Metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with current standard-of-care therapies. Homologous recombination repair (HRR) gene alterations, including BRCA1/2 alterations, can sensitize cancer cells to poly (ADP-ribose) polymerase inhibition, which may improve outcomes in treatment-naïve mCRPC when combined with androgen receptor signaling inhibition.
Type
journal article